Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb open-label implementation trial of long-acting cabotegravir + rilpivirine in HIV-1 infection
2020-000424-19Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Started Jun 2020; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2020-000424-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000424-19.